Skip Navigation Links.
Collapse <span class="m110 colortj mt20 fontw700">Volume 12 (2024)</span>Volume 12 (2024)
Collapse <span class="m110 colortj mt20 fontw700">Volume 11 (2023)</span>Volume 11 (2023)
Collapse <span class="m110 colortj mt20 fontw700">Volume 10 (2022)</span>Volume 10 (2022)
Collapse <span class="m110 colortj mt20 fontw700">Volume 9 (2021)</span>Volume 9 (2021)
Collapse <span class="m110 colortj mt20 fontw700">Volume 8 (2020)</span>Volume 8 (2020)
Collapse <span class="m110 colortj mt20 fontw700">Volume 7 (2019)</span>Volume 7 (2019)
Collapse <span class="m110 colortj mt20 fontw700">Volume 6 (2018)</span>Volume 6 (2018)
Collapse <span class="m110 colortj mt20 fontw700">Volume 5 (2017)</span>Volume 5 (2017)
Collapse <span class="m110 colortj mt20 fontw700">Volume 4 (2016)</span>Volume 4 (2016)
Collapse <span class="m110 colortj mt20 fontw700">Volume 3 (2015)</span>Volume 3 (2015)
Collapse <span class="m110 colortj mt20 fontw700">Volume 2 (2014)</span>Volume 2 (2014)
Collapse <span class="m110 colortj mt20 fontw700">Volume 1 (2013)</span>Volume 1 (2013)
American Journal of Medical Case Reports. 2016, 4(5), 175-179
DOI: 10.12691/AJMCR-4-5-9
Original Research

Case Report: A 12-Year History of Autoimmune Disease Systemic Lupus Erythematosus

Eva Kovacs-Benke1,

1Cancer Immunology Research, 4127 Birsfelden, Switzerland

Pub. Date: May 30, 2016
Full Text PDF

Cite this paper

Eva Kovacs-Benke. Case Report: A 12-Year History of Autoimmune Disease Systemic Lupus Erythematosus. American Journal of Medical Case Reports. 2016; 4(5):175-179. doi: 10.12691/AJMCR-4-5-9

Abstract

Systemic lupus erythematosus (SLE) is a chronic, autoimmune, connective tissue disorder with multi-organ involvement. Reported here is the case of a 33-year-young women with a 12-year history of lupus erythematosus. The article documents the development of lupus: First phase/ preliminary phase (13-21 years of life); Second phase/acute cutaneous lupus erythematosus (22-27 years of life); Third phase/systemic lupus erythematosus (from 28 years of life). The parameters of serological test and blood test were measured regularly during the course of the disease. The MRI-investigation was carried out three times. The clinical symptoms are evaluated in relation to the laboratory parameters All these data with the therapeutic modalities and the trigger factor(s) are disclosed.

Keywords

autoimmune disease, lupus erythematosus cutaneous, systemic lupus erythematosus, corticosteroids

Copyright

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]  Bertsias GK., Salmon JE., Boumpas DT. Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. Ann Rheum Dis, 2010a, 69:1603-11.
 
[2]  Lam GKW, Petri M. Assessment of systemic lupus erythematosus. Clin Exp Rheumatol, 2005, 23: (Suppl. 39).
 
[3]  Al Sawah S., Zhang X., Zhu B., Magder L.S., et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus. The Hopkins Lupus Cohort. Lupus Sci Med. 2015, 2(1): e000066.
 
[4]  O'Byrne KJ., Dalgleish AG., Browning MJ., Steward WP., Harris AL. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer,2000, 36(2):151-69.
 
[5]  Drucker AM., Mussani F., Ibañez D., Siddha S., et al. Cutaneous disease is associated with higher early systemic lupus disease activity. Division of Dermatology, University Health Network, Toronto.
 
[6]  Ahn GE. and Ramsey-Goldmam R. Fatigue in systemic lupus erythematosus. Int J Clin Rheumtol, 2012, 7(2): 217-227.
 
[7]  Sá Ribeiro D., De Araújo Neto C., D'Almeida F., Loureiro Galvão V., et al. Imaging findings of musculoskeletal disorders associated with systemic lupus erythematosus. Radiol Bras, 2011, 44 (1): 52-58
 
[8]  Nadira U., Cader RU., Norella C.T., Kong NCT., et al. Systemic lupus erythematosus with a non functioning pituitary macroadenoma. Am J Case Rep, 2012, 13: 160-162.
 
[9]  Graham JW., Jan W. MRI and the brain in systemic lupus erythematosus. Lupus, 2003, 12: 891-896.
 
[10]  Kimura A., Sakurai T., Tanaka Y., Hozumi I., et al. Proteomic analysis of autoantibodies in neuropsychiatric systemic lupus erythematosus patient with white matter hyperintensities on brain MRI. Lupus, 2008, 17(1):16-20.
 
[11]  Ferreira S., Vasconcelos J., Marinho A., Farinha F., et al. CD4 lymphocytopenia in systemic lupus erythematosus. Acta Reumatol Port, 2009, 34 (2a): 200-206.
 
[12]  Maeda N., Sekigawa I., Iida N.,Matsumoto M., et al. Relationship between CD4+/CD8+ T Cell Ratio and T Cell Activation in Systemic Lupus Erythematosus. Scandinavian Journal of Rheumatology, 1999, 28 (3): 160-170.
 
[13]  Cozzani E., Drosera M., Gasparini G., and Parodi A. Serology of Lupus Erythematosus: Correlation between Immunopathological Features and Clinical Aspects. Autoimmune Diseases, 2014, 28: ID 321359, 13 pages.
 
[14]  Rahmen A. Drug treatment of systemic lupus erythematosus. The Pharmaceutical Journal, 2009, 1 AUG.
 
[15]  Stojanovich L, Marisavljevich D. Stress as a trigger of autoimmune disease. Autoimmune Re, 2008, 7(3):209-13.
 
[16]  Roussou E., Iacovou C., Weerakoon A., Ahmed K. Stress as a trigger of disease flares in SLE. Rheumatol Int, 2013, 33(5):1367-70.
 
[17]  Mastorakos G., Chrousos GP., Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab, 1993, 77:1690-4.